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This is one of several articles we think you will
find of interest that are part of our special issue
of Kidney International addressing the chal-The aim of this study was to estimate the incidence of
COVID-19 disease in the French national population of
dialysis patients, their course of illness and to identify the
risk factors associated with mortality. Our study included all
patients on dialysis recorded in the French REIN Registry in
April 2020. Clinical characteristics at last follow-up and the
evolution of COVID-19 illness severity over time were
recorded for diagnosed cases (either suspicious clinical
symptoms, characteristic signs on the chest scan or a
positive reverse transcription polymerase chain reaction)
for SARS-CoV-2. A total of 1,621 infected patients were
reported on the REIN registry from March 16th, 2020 to
May 4th, 2020. Of these, 344 died. The prevalence of
COVID-19 patients varied from less than 1% to 10%
between regions. The probability of being a case was
higher in males, patients with diabetes, those in need of
assistance for transfer or treated at a self-care unit. Dialysis
at home was associated with a lower probability of being
infected as was being a smoker, a former smoker, having
an active malignancy, or peripheral vascular disease.
Mortality in diagnosed cases (21%) was associated with the
same causes as in the general population. Higher age,
hypoalbuminemia and the presence of an ischemic heart
disease were statistically independently associated with a
higher risk of death. Being treated at a selfcare unit was
associated with a lower risk. Thus, our study showed a
relatively low frequency of COVID-19 among dialysis
patients contrary to what might have been assumed.
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D ue to their frequent contact with hospitals and theircomorbid condition, dialysis patients are identified ashigh-risk patients for severe forms of infection from
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). Guidelines to mitigating risks have been pub-
lished.1–7 However, few studies, including case reports and
the experience of centers, have included sufficient numbers
of patients to have a complete overview of their real risk
and course of illness.8–16 In those studies, case fatality varied
from 14% to 31%.
On March 16th, 2020, the French national end-stage
kidney disease renal epidemiology and information network
(REIN) registry began to record all patients on dialysis in
France who were diagnosed with coronavirus disease 2019
(COVID-19).
The aim of this first report from the French REIN registry
is to describe the population of infected dialysis patients and
their course of illness, estimate the incidence and lethality of
COVID-19, and identify the risk factors associated with the
probability of death.lenges of dialysis and transplantation during
the COVID-19 pandemic. Please also find
additional material in our commentaries and
letters to the editor sections. We hope these
insights will help you in the daily care of your
own patients.
1519
c l i n i ca l i nves t iga t i on C Couchoud et al.: SARS-CoV-2 in the French cohort of dialysis patientsRESULTS
From March 16th, 2020 to May 4th, 2020, a total of 1621
patients were listed as being infected with SARS-CoV-2 in the
REIN registry. This number represents 3.3% of all 48,669
dialysis patients treated in 1245 dialysis units in metropolitan
France and overseas territories.
The clinical and care situation for the first report in the
registry was “hospitalized— moderate disease” for 48%,
“mild disease treated at home” for 39%, “severe disease in an
intensive care unit” for 5%, “death” for 2%, and “asymp-
tomatic” for 2% of cases. The first diagnosis was made in 73%
of cases with a polymerase chain reaction analysis on a
nasopharyngeal swab, 17% on characteristic signs on the
computed tomography scan, and 8% on suspicious clinical
symptoms. Finally, a positive polymerase chain reaction
analysis was available for 1269 patients (79%).
In all, 38% were treated at home. Outpatients, compared
with inpatients, were younger (median age: 68.7 years,
interquartile range [IQR] 56.7–80.4 vs. 73.7 years, IQR 63.7–
81.6, respectively), were more often nonsmokers, and had less
dysrhythmia and incapacity for transfer (Supplementary
Table S1). Their mortality level was lower (8.5%) compared
to that for patients who were hospitalized (22.4%).
In all, 9% of patients were admitted to an intensive-care
unit. Those patients were younger than the others (median
age 67.2 years, IQR 58.3–74.5 vs. 72.4, IQR 61.3–81.6), less
often had cerebrovascular disease, had a higher body mass
index, and were less often treated by hospital-based hemo-
dialysis (Supplementary Table S2). Among the 87 patients for
whom information was available, 51% received invasive me-
chanical ventilation (Supplementary Figure S1). The mortal-
ity level of intensive-care unit patients was higher (34%) than
that for patients who were not admitted to intensive-care
units (15.5%).
The clinical situation at the last report in the registry for
patients who were still alive was “hospitalized—moderate dis-
ease” for 11%, “mild disease treated at home” for 16%, “in
intensive care” for 2%, “recovered” for 67%, and “asymptom-
atic” for 4%, with a median follow-up of 19 days (IQR 6–28).
Not all parts of France were affected in the same way. The
prevalence of COVID-19 patients varied from less than 1% in
the 5 overseas territories and 8 metropolitan regions to over
5% in 3 northeastern regions (especially in Alsace, at 10%,
one of the first French clusters) and in the Île-de-France
(9%), the most densely populated region (Figure 1). These
variations were not explained by age and were parallel to
those in the general population (Figure 1). At that time, the
percentage of infected persons in the French population was
0.2%, and the mortality level among confirmed cases was
19% (no systematic screening). The cumulative incidence of
new cases, after an exponential increase, has now stabilized
(Figure 2).
The control group, selected from dialysis units where there
was at least 1 COVID-19 patient, included 25,455 dialysis
patients in 689 dialysis units. In these dialysis units, the
incidence of COVID-19 infection was 6%.1520The clinical characteristics of infected dialysis and
control populations are represented in Table 1. Compared
to the 25,455 selected controls (treated in centers where at
least 1 patient was infected), the probability of being a case
was higher in male patients (odds ratio [OR] 1.2, 95%
confidence interval [CI] 1.1–1.4), patients with diabetes
(OR 1.3, 95% CI 1.1–1.4), those in need of assistance for
transfer (OR 1.5, 95% CI 1.3–1.8), and those being treated
in a self-care unit (OR 1.3, 95% CI 1.0–1.6), compared
with those receiving hospital-based dialysis (stepwise
logistics regression). Age was not associated with the
probability of being infected. Undergoing dialysis at home
was associated with a lower probability of being infected
(OR 0.6, 95% CI 0.4–0. 8), as was being a smoker (OR
0.5, 95% CI 0.4–0.7) or former smoker (OR 0.8, 95% CI
0.47–0.98), having an active malignancy (OR 0.8, 95% CI
0.7–0.99), and having peripheral vascular disease (OR 0.8,
95% CI 0.7–0.9). Adjusted for age, comorbidities, and
modality of treatment, compared to living in Rhône-
Alpes, living in the Île-de-France (OR 3.1, 95% CI 2.4–
4.0) or the northeast—Alsace (OR 3.2, 95% CI 2.3–4.3),
Lorraine (OR 1.7, 95% CI 1.2–2.4), Picardy (OR 1.6, 95%
CI 1–2.3), and Franche-Comté (OR 1.8, 95% CI 1.0–
3.0)—was associated with a higher probability of being
infected.
Among the infected patients, 344 died due to a cause
related to SARS-CoV-2, after a median time of 6 days (IQR 3–
13). The lethality in diagnosed cases was 21%. In the uni-
variate analysis, higher age, being a former smoker, having a
chronic respiratory disease, cardiovascular comorbidities
(e.g., peripheral vascular disease, ischemic heart disease,
congestive heart failure, and dysrhythmia), and frailty
(hypoalbuminemia or inability to walk) were associated with
a higher risk of death in SARS-CoV-2–infected dialysis pa-
tients. Receiving dialysis in self-care units or outpatient cen-
ters, as well as being a current smoker, was associated with a
lower risk of death. In fact, most of these clinical character-
istics and care were associated with older age. In the multi-
variate model, only older age, hypoalbuminemia, and the
presence of an ischemic heart disease were statistically inde-
pendently associated with a higher risk of death (Table 2).
Being treated in a self-care unit was associated with a lower
risk of death. Chronic respiratory disease, obesity, diabetes,
and smoking status were not associated with a higher risk of
death. The sensitivity analysis including the region of treat-
ment gave similar results.
The trajectory of care is represented in Figure 3 for the 287
deceased patients for whom at least 2 different clinical situ-
ations were reported in the registry. For severe cases hospi-
talized in intensive-care units, the median time until death
was 7 days (IQR 4–14), whereas the median time for hospi-
talized patients until death was 5 days (IQR 3–9) and, for
patients at home, 6 days (IQR 3–11).
The trajectory of care is represented in Figure 4 for the 799
patients who recovered (clinical situation coded as recovery or
asymptomatic). The median time in hospital until recoveryKidney International (2020) 98, 1519–1529
Figure 1 | Spatial distribution of infected patients on dialysis and in the general population. SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2.
C Couchoud et al.: SARS-CoV-2 in the French cohort of dialysis patients c l i n i ca l i nves t iga t ionwas 15 days (IQR 10–21), similar to that for patients who
were at home (16 days, IQR 11–21).
DISCUSSION
So far, more than 1600 dialysis patients have been diagnosed
with SARS-CoV-2 infection in France. Our study shows that
the prevalence of SARS-CoV-2 infection in dialysis patients
varied throughout the country, from 0% to 10%. The mor-
tality level in this population of diagnosed cases is high, atKidney International (2020) 98, 1519–152921%, and is mainly associated with higher age (13% mortality
level in patients aged <75 years compared with 30% in pa-
tients aged >75 years).
The trend of the SARS-CoV-2 epidemic in patients on
dialysis shows a development parallel to that in the general
French population, with northeastern regions and the Île-de-
France being more affected. Our global prevalence is 3% of
dialysis patients, but this reaches 10% in the most-affected
regions. In the absence of other population-based data, the1521
Figure 2 | Cumulative number of dialysis patients with coronavirus disease (COVID) 2019.
c l i n i ca l i nves t iga t i on C Couchoud et al.: SARS-CoV-2 in the French cohort of dialysis patientsprevalence can be compared with only the 14% of the He-
modialysis Center of Wuhan No.1 Hospital at the epicenter of
the Chinese epidemic.12 However, the nonsystematic detec-
tion of asymptomatic patients in France may lead to an un-
derestimation of the true distribution of SARS-CoV-2 in the
French dialysis population.
Although the lockdown seemed to have significantly
reduced the amount of contact among the general population,
dialysis patients have to leave confinement to go to their
dialysis units and are consequently still in contact with a large
number of people. The risk of exposure may occur during
transport, at the dialysis unit, or during hospitalization, but
also at home with family or caregivers. Home dialysis was
associated with a lower probability of being infected, sug-
gesting a protective effect of staying at home. Dialysis centers
that were affected later on learned from units contaminated
early on in the epidemic’s progression and reorganized their
patients’ circulation and care.14,17 Indeed, since the beginning
of the epidemic, protective strategies have been broadcast by
the Société Francophone de Nephrology Dialyse
Transplantation, with weekly COVID-19 webinars inviting
all French nephrologists to discuss the overall COVID-19
themes and topics available on the the organization’s1522website.18 Thanks to this collaboration, the worst may have
been avoided. However, we must now remain vigilant and
protect our healthcare workers.
The initial incidence of the disease in some dialysis units
seemed very high, especially in the initially affected regions.
The incidence in dialysis units is now decreasing, mirroring
the decrease in the general population. This decrease also can
be associated with the implementation of all the necessary
preventive actions promoted by the Société Francophone de
Nephrology Dialyse Transplantation, including (i) wearing a
mask during transport and for the entire period of care, (ii)
systematic tracking of patients and screening at the entrance
to dialysis units based on fever and symptoms or contact with
an infected person, and (iii) restricting areas in which there
are COVID-19 cases.19
As in the general population, male gender, diabetes, and
frailty, but not age, were associated with a higher risk of being
infected. Selection bias, due to the fact that these patients may
have a more severe form of the disease and therefore are more
easily diagnosed, cannot be ruled out. As in the cohort of 627
hemodialysis patients at the hemodialysis center in Wuhan,
diabetes was associated with a higher risk of infection. This
result was still significant when introducing regions in theKidney International (2020) 98, 1519–1529
Table 1 | Clinical characteristics and method of treatment for
COVID-19 patients and for the 2 control groups (selection of
patients from dialysis units with at least 1 confirmed COVID-19




















RRT duration, yr 3.3 (1.4–6.9) 3.6 (1.6–7.3) 3.8 (1.8–7.7) 0
Women 36.2 39.2 39.0 0.0
Age, yr
0–64 32.6 30.3 31.8 0.0
65–74 26.3 26.5 26.9 0.0
75–84 26.2 27.6 26.7 0.0
$85 15.1 15.7 14.7 0.0
Smoker 7.5 11.9 12.3 13.2




15.5 16.3 15.8 2.9




23.0 24.3 24.4 3.4
Cerebrovascular
disease
12.7 12.9 12.5 2.4
Ischemic heart
disease
27.2 28.1 27.1 2.7
Dysrhythmia 21.7 25.0 23.6 2.4
Congestive heart
failure




4.6 4.9 4.1 6.6
Need assistance
for transfer
15.7 12.7 11.2 6.6
Diabetes 50.8 45.3 44.5 1.0
BMI, kg/m2
<18.5 4.0 5.6 5.2 7.9
18.5–25 37.9 39.6 39.5 7.9
25–30 31.4 30.6 30.8 7.9
$30 26.6 24.2 24.5 7.9
Albuminemia, g/l
>35 63.1 65.1 67.8 7.2
30–35 25.8 24.2 22.9 7.2
$35 11.2 10.7 9.3 7.2
Hemodialysis
Hospital 65.0 64.1 54.1 0.0
Outpatient center 22.0 21.4 23.6 0.0
Self-care unit 9.7 7.9 15.9 0.0
Home (includes
PD also)
3.3 6.6 6.4 0.0
BMI, body mass index; COVID-19, coronavirus disease 2019; PD, peritoneal dialysis;
RRT, renal replacement therapy.
Values are % or median (interquartile range), unless otherwise indicated.
C Couchoud et al.: SARS-CoV-2 in the French cohort of dialysis patients c l i n i ca l i nves t iga t ionmodel to take into account the fact that the epidemic was
mainly located in northeast France where the prevalence of
diabetes is higher. Smoking, even after taking comorbidities
into account, was associated with a lower risk of infection, as
discussed, in the general population.20 Surprisingly, being
treated in a self-care unit was associated with a higher risk of
being infected. At self-care units, care is provided withoutKidney International (2020) 98, 1519–1529supervision by an onsite nephrologist.16 The presence of a
nurse is mandatory, and patients are helped with the hemo-
dialysis process. All these units collaborate with a hospital-
based dialysis unit. Moreover, these units treat younger pa-
tients, who may have had more contact risk than elderly
patients. These small units, with fewer caregivers on site, may
have been slower to implement protection strategies, as
proposed by others.1 Further analyses are required to evaluate
the impact of other risk factors, such as living in an institu-
tion or in a deprived neighborhood area associated with
overcrowded housing.
International comparison of case fatalities should be made
with caution, given the case mix, the various healthcare ar-
rangements, and the various dynamics of the epidemic. Our
mortality level among diagnosed cases, 21% so far, is higher
than the 13% reported for the dialysis center in Wuhan.12 The
older age and more-frequent comorbidities of French dialysis
patients may explain a higher mortality level than that in
China.21,22 Furthermore, the nonsystematic detection of
asymptomatic patients favors more seriously ill patients. In
France, the case fatality rate was lower than the 29% reported
in 4 outpatient dialysis facilities in Italy,14 the 30% in a single
center in Madrid,15 or the 31% in a single center in New
York.16 A higher mortality level in these studies may be
explained by a selection bias for more severely ill hospitalized
patients. Compared to that in the general population, the
dialysis lethality rate observed in our cohort was similar to the
20% case fatality rate observed in Italy among patients aged
>80 years.21 It is also similar to the mortality rate for
confirmed cases in the French general population, where at
least 84% of the people who died had a comorbid condition,
and 92% were aged $65 years.
Apart from age, which seems to be the major factor in
the general population,23 nutritional status, indirectly
assessed by albumin levels and the presence of ischemic
heart disease, seems to be the main risk factor. Further in-
depth analyses are planned in order to better estimate the
excess mortality level among these dialysis patients, taking
into account the underlying mortality risk compared with
another period and the non–COVID-19 mortality level.
Being treated in a self-care unit was associated with a lower
mortality level, even after taking into account age and
comorbidities. After adjustment, the mortality level for
those on home dialysis did not differ from the mortality
rate for those on hospital-based hemodialysis. However,
the small number of patients with home dialysis has not
allowed us to make an in-depth analysis so far. Other
factors (such as living conditions, delay in alerting, and
other home-based care), which are not available in our
registry, need to be explored.
Although data are incomplete, the illness trajectory seems
to show rapid worsening and a slow healing process. The
short lapse of time before death could corroborate the
physiopathology with the delay in host inflammatory
response phase reported 7 to 10 days after the initial infec-
tion.24 This rapid negative development raises the question of1523
Table 2 | Clinical characteristics and method of treatment in COVID patients according to their living status and risk factors
associated with the probability of death (stepwise logistics regression)
Patients’ characteristics
Living cases Deceased cases Death Crude OR Final model
(col %) (col %) (row %) Inf Sup Inf Sup
Female 36.6 34.9 20.4 Ref
Male 63.4 65.1 21.7 1.1 0.8 1.4
Age, yr
0–44 9.8 2.0 5.3 Ref Ref
45–64 37.8 13.4 9.9 2.0 0.9 4.5 1.6 0.6 4.4
65–74 26.7 25.0 20.1 4.5 2.0 10.0 3.7 1.4 9.6
75–84 23.4 36.9 29.9 7.6 3.5 16.8 5.4 2.1 14.1
$85 12.4 25.2 35.4 9.8 4.4 21.9 6.2 2.4 16.5
Never smoker 8.5 3.7 20.0 Ref
Ex-smoker 24.8 33.7 26.9 1.5 1.1 1.9
Smoker 8.5 3.7 10.5 0.5 0.3 0.9
Chronic respiratory disease 14.3 20.4 27.6 1.5 1.1 2.1
Cancer 9.5 8.8 19.9 0.9 0.6 1.4
Peripheral vascular disease 21.2 29.9 27.5 1.6 1.2 2.2
Cerebrovascular disease 12.3 14.1 23.4 1.1 0.8 1.6
Ischemic heart disease 24.7 36.4 28.2 1.8 1.4 2.3 1.6 1.1 2.1
Dysrhythmia 19.4 30.6 29.7 2.0 1.5 2.7
Congestive heart failure 21.2 27.9 26.0 1.5 1.1 2.1
Totally dependent for transfer 3.8 7.7 35.7 2.2 1.3 3.9
Need assistance for transfer 14.1 21.6 29.3 1.9 1.4 2.7
Walk without help 80.2 68.2 18.7 Ref
Diabetes 49.5 55.5 23.2 1.2 1.0 1.6
BMI, kg/m2
<18.5 4.0 4.1 21.8 1.1 0.5 2.2
18.5–25 38.2 37.1 20.8 Ref
25–30 30.4 35.4 24.0 1.2 0.8 1.6
$30 27.5 23.4 18.7 0.8 0.5 1.1
Albuminemia, g/l
>35 65.1 55.7 18.5 Ref Ref
30–35 25.1 28.2 22.9 1.5 1.1 2.0 1.3 0.9 1.9
$35 9.8 16.2 30.3 2.2 1.4 3.5 1.8 1.1 3.0
Hemodialysis
Hospital 62.7 73.3 24.0 Ref Ref
Outpatient center 23.4 17.2 16.5 0.6 0.4 0.9 0.8 0.5 1.1
Self-care unit 11.2 4.1 8.9 0.3 0.1 0.5 0.4 0.2 0.8
Home (includes PD also) 2.7 5.5 35.2 1.5 0.7 3.0 1.8 0.8 3.8
BMI, body mass index; col, column; COVID, coronavirus disease; Inf, inferior; OR, odds ratio; PD, peritoneal dialysis; Ref, referent; RRT, renal replacement therapy; Sup, superior.
c l i n i ca l i nves t iga t i on C Couchoud et al.: SARS-CoV-2 in the French cohort of dialysis patientswhether provision can be made for reinforced surveillance at
home and during dialysis sessions, and preventive hospitali-
zation in a safe environment. Our definition of recovery
should be assessed with caution, as the definition of recovery
is still under debate. Some patients were maintained in the
hospital under isolation for 15 days.
Very soon after the start of the epidemic, the French-
speaking Society of Nephrology, helped by infectious disease
specialists, made the recommendation that for each dialysis
patient with fever, a viral syndrome, pulmonary symptoms, or
diarrhea, a computed tomography scan be prescribed, as well
as a polymerase chain reaction test on a nasopharyngeal swab.
Contact subjects were also tested in the later period, explaining
the occurrence of a few asymptomatic patients. These recom-
mendations applied to all hospitalized patients and outpatients
as well, throughout the country. However, due to possible
variations in diagnosis strategies, day 1 for each patient may
vary from one unit to another. Access to intensive-care units
was a concern for nephrologists in certain areas. Some tensions
could be noted in highly affected regions, but in general,1524dialysis patients could be transferred to intensive care as
required depending on their age and comorbidities.
The strength of this study is its national scale, including
the whole population of French dialysis patients. However,
these results must be interpreted bearing the following limi-
tations in mind. Various screening strategies may influence
the detection of the disease. This could especially be the case
for patients treated at home or asymptomatic patients or
those undergoing sudden death, but mild cases and hospi-
talized patients can be considered exhaustive. Nonsystematic
screening favors the collection of more-severe cases and leads
to an overestimation of lethality. The second limitation is the
lack of granular data on clinical presentation, laboratory re-
sults and treatment, and the precise protective strategy
implemented in the units. Our study is based on a registry,
which gives an exhaustive national overview but with a
limited dataset—not on medical records, which could give
more detailed data on treatment and clinical presentation, but
on a limited number of patients with a risk of selection bias.
Third, due to the confinement of registry research assistants,Kidney International (2020) 98, 1519–1529
DeathHome Intensive-care unitHospitalization
N = 16, median = 4, IQR = 3 –6 N = 53, median = 7, IQR = 4–14 N = 22,  median 3, IQR = 1–6 
N = 33, median = 6, IQR = 3–11
N = 200, median = 5, IQR = 3–9 
N = 3, median = 13, IQR = 2–14
Death n =  287
Figure 3 | Care trajectory, before death, for 287 patients (number of patients and median and interquartile range [IQR] number of
days before transfer).
C Couchoud et al.: SARS-CoV-2 in the French cohort of dialysis patients c l i n i ca l i nves t iga t ionthe data-quality control procedure was limited. Post hoc
controls will be taking place to complete the data. Fourth, the
total number of patients tested and not considered to be
COVID positive is unknown. As in the general population,
the true lethality of COVID-19 in infected dialysis patients
needs to be confirmed by a longer follow-up and deployment
of screening methods.
Conclusion
Despite the difficulty of having a “true” estimation, this
preliminary report of the French registry shows a relatively
low frequency of COVID-19 among dialysis patients, contrary
to what might have been feared, but as in the generalIntensive-care unit Hospitalization
N = 137, median = N = 17, median = 7, IQR = 4–12
N
N = 23, median = 31, IQR = 19–49
N = 3, median = 20, IQ
Recovery n = 799
Figure 4 | Care trajectory, before recovery, for 799 patients (number
days before transfer).
Kidney International (2020) 98, 1519–1529population, the epidemic did not evenly affect the whole
territory. The mortality level in diagnosed cases (21%) is
associated with the same causes as in the general population,
namely, advanced age, frailty, and comorbid conditions.METHODS
Population
The French REIN registry is intended to include all end-stage renal
disease patients on renal replacement therapy living in France,
including overseas territories. Patients with a diagnosis of acute renal
failure were excluded, that is, those who recovered all or some renal
function within 45 days or were considered by experts to have acute
failure when they died before 45 days. The details of organizationalRecoveryHome
N = 453, median = 20, IQR = 14–29 10, IQR = 5–13 
 = 324, median = 19, IQR = 12– 28 
R  = 16– 23
of patients and median and interquartile range [IQR] number of
1525
c l i n i ca l i nves t iga t i on C Couchoud et al.: SARS-CoV-2 in the French cohort of dialysis patientsprinciples and quality control are described elsewhere.25 The REIN
network includes nephrologists, nurses, patients, public health rep-
resentatives, and epidemiologists coordinated within regional and
national steering committees. The national coordination center is
based at the Agence de la Biomédecine, a public health agency that
oversees the activity of organ and tissue procurement and trans-
plantation. The REIN registry is supported by the National Health
Insurance Funds and the Ministry of Health. Although participation
in the registry is not mandatory, dialysis centers are strongly
encouraged to participate, as new regulations on renal replacement
therapy require the regular provision of data to administrative
agencies. The participation rate of centers in all contributing regions
is 100%. Thirty-two clinical research assistants regularly visit each
dialysis center to check the completeness of patient and event
registration and to ensure the quality of data. This study included all
patients on dialysis on the French mainland and French overseas
territories in April 2020. Data were extracted on May 4th, 2020. A
new extraction was made on June 22nd to update patients’ follow-
up.
Information
Clinical characteristics at last follow-up included age, gender,
comorbidities, mobility status (walks without help, needs assistance
for transfers, or is totally dependent for transfers), body mass index,
tobacco use, hemoglobin and serum albumin levels, dialysis tech-
nique (hemodialysis or peritoneal dialysis) and location (hospital-
based, outpatient center, self-care unit, home). This study analyzed
10 comorbidities: diabetes, congestive heart failure, ischemic heart
disease, peripheral vascular disease, aortic aneurysm, cerebrovascular
disease, dysrhythmia, active malignancy, cirrhosis, and severe
behavioral disorders (defined as including dementia, psychosis, or
severe neurosis that may have affected the functional status or
adherence to treatment).
The last residence and last dialysis unit before February 15,
2020 were taken into account to avoid misclassification of pa-
tients transferred to another dialysis center due to their infection
status.
With the help of the REIN clinical research assistants, in the
presence of either suspicious clinical symptoms, characteristic signs
on the chest scan, or a positive reverse transcription polymerase
chain reaction for SARS-CoV-2 on a nasopharyngeal swab, the ne-
phrologists declared infection by SARS-CoV-2 on the registry.
The clinical and care status declaration was categorized into 7
groups measuring the severity of the illness over time: asymptomatic;
mild disease treated at home; hospitalized—moderate disease; severe
disease in an intensive-care unit; death; recovered; other. The date of
the first report to the registry was the date of diagnosis. Each
modification to the clinical status was reported on occurrence. For
the purpose of this study, recovery was defined as either asymp-
tomatic or recovered. Patients were also classified according to the
ordinal scale proposed by the World Health Organization.26
Analysis
The clinical characteristics of patients were expressed as frequencies
and percentages for qualitative variables, and medians with inter-
quartile ranges for quantitative variables.
The percentage of infected patients in the dialysis units of each
region was adjusted on age (indirect standardization) to take into
account the underlying age distribution of the dialyzed patients. The
crude ratio and the standardized ratio are presented on a map, ac-
cording to the patients’ area of residence. To give an overview of the1526epidemic in France, the hospital mortality level due to COVID-19 in
April 2020, extracted from the platform of the national public health
agency—Santé Publique France27—was reported.
We also presented the cumulative number of infected patients on
a day-to-day graph for the whole country.
To describe the characteristics of infected patients, we compared
this population with 2 control groups. The first one included all the
dialysis patients in France who were not infected. The second, to take
into account the heterogeneity of the distribution of the epidemic in
the country, included only patients treated in the dialysis units where
at least one infected patient had been declared. Risk factors associ-
ated with being a case in those units were analyzed by logistics
regression with a stepwise selection of variables. The final model is
based on complete data (no imputation). A P-value of <0.05 (2-
sided) was considered statistically significant. Results are reported
as OR with 95% confidence interval.
Lethality was estimated from the proportion of deceased patients
among the diagnosed cases. To identify the risk factors associated
with death in SARS-CoV-2 dialysis patients, a logistics regression
with stepwise selection of variables was used. Interactions between
age and other factors were explored. A P-value of <0.05 (2-sided)
was considered statistically significant. Results are reported as OR
with 95% confidence interval. Sensitivity analyses were made
including the region of treatment, either as a fixed effect or with a
random intercept.
Finally, when available, the course of illness was represented on a
graph to describe the process of care for patients who died and for
those who recovered. For each transition between the various care
statuses, the number of patients and the median duration before
transfer were calculated.APPENDIX
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